By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acuity Pharmaceuticals (Merger with Froptix and eXegenics to Create Opko Corporation) 

Press releases archived for reference only.
3701 Market Street
Philadelphia  Pennsylvania  19104  U.S.A.
Phone: n/a Fax: n/a




Company News
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye 3/27/2007 1:07:26 PM
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President Of Clinical Development 10/24/2006 11:09:14 AM
Acuity Pharmaceuticals Reports Positive Phase II Results For Bevasiranib In Wet AMD 9/11/2006 8:15:38 AM
Acuity Pharmaceuticals And Pathogenics Inc. Announce Preclinical Data Demonstrating Utility Of NCT In Viral Conjunctivitis 8/23/2006 9:08:26 AM
Acuity Pharmaceuticals Reports Positive Initial Phase II Results For Bevasiranib (Cand5) In Wet AMD 6/1/2006 11:02:33 AM
ZaBeCor Pharmaceutical Co. Licenses Its Anti-Inflammatory siRNA Technology To Acuity Pharmaceuticals For Ophthalmic Uses 4/28/2006 10:41:51 AM
Acuity Pharmaceuticals Continues Pipeline Expansion By Licensing A Novel Broad Spectrum Anti-Infective For Ophthalmic Use 4/20/2006 11:22:32 AM
Acuity Pharmaceuticals Completes Patient Enrollment In Phase II Trial In Wet AMD And Initiates New Trial In Diabetic Macular Edema 2/2/2006 10:39:19 AM
Acuity Pharmaceuticals To Present At Rodman & Renshaw Healthcare Conference 11/4/2005 12:59:46 PM
Acuity Pharmaceuticals Initiates Phase II Trial Of Cand5 In Wet AMD Following Successful Completion Of Phase I10/19/2005 5:13:21 PM